Literature DB >> 16157102

Expression of phosphodiesterase 5 in maternal and fetal sheep.

Kristin H Coppage1, XuMing Sun, R Scott Baker, Kenneth E Clark.   

Abstract

OBJECTIVE: Ovine pregnancy is associated with elevated levels of nitric oxide. Nitric oxide stimulates cyclic guanosine monophosphate (cGMP), which results in vascular smooth muscle relaxation/vasodilation. Phosphodiesterase type 5 regulates cGMP in the urogenital track. The present study was designed to determine message expression of phosphodiesterase type 5 in the myometrium, uterine vessels, and placentome of the sheep and phosphodiesterase type 5 protein expression in the maternal and fetal placentome. STUDY
DESIGN: Tissue was collected from 5 nonpregnant and 5 pregnant anesthetized animals (gestational day = 134 +/- 4) and frozen at -80 degrees C. Optimized reverse transcription-polymerase chain reaction was performed on all tissues, and immunohistochemistry was performed on the placentome only.
RESULTS: Phosphodiesterase type 5 messenger ribonucleic acid levels were significantly higher in the myometrium and placentome, compared with the maternal blood vessels. Phosphodiesterase type 5 protein was immuno-localized to the vascular smooth muscle of the maternal vessels, stroma, and placental capsule only.
CONCLUSION: Although phosphodiesterase type 5 messenger ribonucleic acid was present in the fetal placenta, phosphodiesterase type 5 protein was expressed only in maternally derived placental tissue. This suggests that regulation of cGMP levels and vascular tone in the umbilical circulation differs from the uterine circulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157102     DOI: 10.1016/j.ajog.2005.05.054

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

1.  Genome-wide copy number variation in Hanwoo, Black Angus, and Holstein cattle.

Authors:  Jung-Woo Choi; Kyung-Tai Lee; Xiaoping Liao; Paul Stothard; Hyeon-Seung An; Sungmin Ahn; Seunghwan Lee; Sung-Yeoun Lee; Stephen S Moore; Tae-Hun Kim
Journal:  Mamm Genome       Date:  2013-03-30       Impact factor: 2.957

Review 2.  Preeclampsia beyond pregnancy: long-term consequences for mother and child.

Authors:  Hannah R Turbeville; Jennifer M Sasser
Journal:  Am J Physiol Renal Physiol       Date:  2020-04-06

3.  Sildenafil Treatment Ameliorates the Maternal Syndrome of Preeclampsia and Rescues Fetal Growth in the Dahl Salt-Sensitive Rat.

Authors:  Ellen E Gillis; Jennifer N Mooney; Michael R Garrett; Joey P Granger; Jennifer M Sasser
Journal:  Hypertension       Date:  2016-01-04       Impact factor: 10.190

Review 4.  New approaches for managing preeclampsia: clues from clinical and basic research.

Authors:  Eric M George
Journal:  Clin Ther       Date:  2014-11-20       Impact factor: 3.393

5.  Sildenafil Prevents Apoptosis of Human First-Trimester Trophoblast Cells Exposed to Oxidative Stress: Possible Role for Nitric Oxide Activation of 3',5'-cyclic Guanosine Monophosphate Signaling.

Authors:  Jay M Bolnick; Brian A Kilburn; Alan D Bolnick; Michael P Diamond; Manvinder Singh; Michael Hertz; Jing Dai; D Randall Armant
Journal:  Reprod Sci       Date:  2014-11-26       Impact factor: 3.060

Review 6.  Mechanisms and potential therapies for preeclampsia.

Authors:  Eric M George; Joey P Granger
Journal:  Curr Hypertens Rep       Date:  2011-08       Impact factor: 5.369

7.  Sildenafil Citrate Does Not Reprogram Risk of Hypertension and Chronic Kidney Disease in Offspring of Preeclamptic Pregnancies in the Dahl SS/Jr Rat.

Authors:  Hannah R Turbeville; Ashley C Johnson; Michael R Garrett; Jennifer M Sasser
Journal:  Kidney360       Date:  2020-04-17

8.  Sildenafil attenuates placental ischemia-induced hypertension.

Authors:  Eric M George; Ana C Palei; Edward A Dent; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-06-19       Impact factor: 3.619

9.  Effects and mechanisms of action of sildenafil citrate in human chorionic arteries.

Authors:  Chrisen H Maharaj; Daniel O'Toole; Tadhg Lynch; John Carney; James Jarman; Brendan D Higgins; John J Morrison; John G Laffey
Journal:  Reprod Biol Endocrinol       Date:  2009-04-23       Impact factor: 5.211

10.  TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial.

Authors:  Takashi Umekawa; Shintaro Maki; Michiko Kubo; Hiroaki Tanaka; Masafumi Nii; Kayo Tanaka; Kazuhiro Osato; Yuki Kamimoto; Satoshi Tamaru; Toru Ogura; Yuki Nishimura; Mayumi Kodera; Chisato Minamide; Masakatsu Nishikawa; Masayuki Endoh; Tadashi Kimura; Tomomi Kotani; Masamitsu Nakamura; Akihiko Sekizawa; Tomoaki Ikeda
Journal:  BMJ Open       Date:  2018-10-30       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.